# A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

> **NCT07583849** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 376 (estimated)

## Conditions studied

- COPD (Chronic Obstructive Pulmonary Disease)

## Interventions

- **DRUG:** HSK39004 Dry Powder Inhaler Simulant
- **DRUG:** HSK39004 Dry Powder Inhaler-0.75mg

## Key facts

- **NCT ID:** NCT07583849
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-24
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 376 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07583849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07583849, "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT07583849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*